家庭干预对获得性脑或脊髓损伤的疗效预测与成本效果评价:一项随机对照试验
该研究基于157例出院后4个月至2年的获得性脑或脊髓损伤患者,探索损伤类型、损伤时间、实施形式和关系对象对家庭干预疗效的预测作用,并从医疗付费方角度进行经济学评价。结果显示4个预测因素对治疗反应影响微小;家庭干预增量成本为798.16欧元(CI: 700.9; 895.5),2个月随访时心理健康总分增量效应为5.64分(CI: 2.71, 8.56),在300欧元支付意愿阈值下成本有效的概率为99.8%。
要点
- 损伤类型、时间、实施形式及关系对象对家庭干预疗效的预测作用可忽略至较小。
- 家庭干预增量成本约798.16欧元,2个月心理健康总分增量效应5.64分。
- 支付意愿阈值300欧元时,家庭干预对心理健康总分的成本有效概率为99.8%。
核心结论
- 预测因素对家庭干预的治疗反应无影响或影响很小。
- 从医疗付费方角度看,家庭干预具有成本有效的概率。
研究设计与样本
- 探索性预测因素分析与基于随机对照试验的经济学评价。
- 157例参与者均在专科神经康复单元出院后4个月至2年入组。
主要发现
- 损伤类型、损伤时间、实施形式和关系对象4个预测因素对治疗反应的影响可忽略至较小。
- 家庭干预增量成本估计为798.16欧元(CI: 700.9; 895.5)。
- 2个月随访时心理健康总分增量健康效应估计为5.64分(CI: 2.71, 8.56)。
关键数值与推荐
- 增量成本基于实施方式计算,增量健康效应报告心理健康及焦虑抑郁症状指标。
- 支付意愿阈值为300欧元时,家庭干预对心理健康总分成本有效的概率为99.8%。
临床怎么用
- 家庭干预可作为获得性脑或脊髓损伤后康复期具有成本效果潜力的干预选择。
- 选择家庭干预时无需依据损伤类型、时间、实施形式或关系对象进行疗效分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To predict treatment response of a family intervention and investigate its cost-effectiveness from a healthcare payer perspective. DESIGN: Explorative predictor analyses and trial-based economic evaluation. SUBJECTS/PATIENTS: Participants (n=157) were enrolled 4 months to 2 years after discharge from a specialized neurorehabilitation unit. METHODS: Injury type, time since injury, delivery format, and relationship (individual with injury vs family member) were explored as predictors of effect using linear mixed-effect regression. Cost-effectiveness was analysed from a healthcare payer perspective, with incremental cost based on delivery. Incremental health effect was reported for measures on mental health and anxiety and depression symptoms. RESULTS: The 4 predictors had negligible to small effects on the treatment response. Incremental cost for the family intervention was estimated at €798.16 (CI: €700.9; €895.5). Incremental health effect was estimated at 5.64 (CI: 2.71, 8.56) points on the Mental Component Summary at 2 months' follow-up. At a willingness-to-pay threshold of €300, the probability of the intervention being cost-effective was 99.8% for the Mental Component Summary. CONCLUSION: The predictors showed no or little effect on the treatment response, and the cost-effectiveness analysis showed the probabilities of the intervention being cost-effective from a health payer perspective.
引用
- Andersen KY, Dornonville de la Cour FH, Wolffbrandt MM, et al. Predicting effect and evaluating cost-effectiveness of a family intervention after acquired brain or spinal cord injury: a randomized controlled trial. J Rehabil Med. 2026. PMID: 41674107. doi:10.2340/jrm.v58.44691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。